23 results
20-F/A
2022 FY
EX-4.9
IPHA
Innate Pharma
20 Apr 23
Annual report (foreign) (amended)
8:47am
, loss, damage, claim, injury, costs or expenses (collectively, “Damages”) that are caused by (whether directly or indirectly):
11.1.1 any failure
20-F
rckuayjdxxlzh958
24 Apr 20
Annual report (foreign)
10:43am
424B4
rsckqvmm
18 Oct 19
Prospectus supplement with pricing info
4:08pm
F-1/A
7ejqwnr6mjtvp
4 Oct 19
Registration statement (foreign) (amended)
4:56pm
F-1
4tg2pp
20 Sep 19
Registration statement (foreign)
4:08pm
F-1
EX-10.1
thka1y drd
20 Sep 19
Registration statement (foreign)
4:08pm
F-1
EX-10.5
a3sy3sjvbu4
20 Sep 19
Registration statement (foreign)
4:08pm
F-1
EX-10.3
qohbm
20 Sep 19
Registration statement (foreign)
4:08pm
F-1
EX-10.4
d69tnk1oq9cq edxr20
20 Sep 19
Registration statement (foreign)
4:08pm
F-1
EX-10.2
a20jy4
20 Sep 19
Registration statement (foreign)
4:08pm
DRS/A
EX-10.3
3bwvova
30 Aug 19
Draft registration statement (amended)
12:00am
DRS/A
EX-10.1
c4m5z182yr4est79
30 Aug 19
Draft registration statement (amended)
12:00am
DRS/A
EX-10.2
za984ro
30 Aug 19
Draft registration statement (amended)
12:00am
DRS/A
1ie r1hzp6um
30 Aug 19
Draft registration statement (amended)
12:00am
DRS/A
EX-10.4
0s1a ltt1
30 Aug 19
Draft registration statement (amended)
12:00am